BioGaia AB (publ) Logo

BioGaia AB (publ)

BIOG-B.ST

(3.2)
Stock Price

104,40 SEK

23.91% ROA

20.71% ROE

27.25x PER

Market Cap.

10.564.555.600,00 SEK

0% DER

6.37% Yield

29.34% NPM

BioGaia AB (publ) Stock Analysis

BioGaia AB (publ) Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

BioGaia AB (publ) Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (21.33%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

4 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

5 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

6 Revenue Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

7 Net Profit Growth

With continuous net profit growth in the past three years, this company demonstrates a strong financial performance, making it an enticing investment opportunity.

8 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (358), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

9 PBV

The stock's high Price-to-Book Value (P/BV) ratio (5.36x) suggests it's overvalued, potentially making it an expensive investment.

10 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

11 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

BioGaia AB (publ) Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

BioGaia AB (publ) Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

BioGaia AB (publ) Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

BioGaia AB (publ) Revenue
Year Revenue Growth
2002 43.107.000
2003 35.650.000 -20.92%
2004 40.438.000 11.84%
2005 59.606.000 32.16%
2006 86.792.000 31.32%
2007 106.580.000 18.57%
2008 145.190.000 26.59%
2009 203.461.000 28.64%
2010 236.033.000 13.8%
2011 314.992.000 25.07%
2012 645.252.000 51.18%
2013 315.875.000 -104.27%
2014 481.802.000 34.44%
2015 483.241.000 0.3%
2016 534.696.000 9.62%
2017 615.003.000 13.06%
2018 741.870.000 17.1%
2019 768.348.000 3.45%
2020 747.077.000 -2.85%
2021 785.111.000 4.84%
2022 1.103.958.000 28.88%
2023 1.270.776.000 13.13%
2023 1.296.506.000 1.98%
2024 1.536.488.000 15.62%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

BioGaia AB (publ) Research and Development Expenses
Year Research and Development Expenses Growth
2002 14.173.000
2003 14.344.000 1.19%
2004 16.297.000 11.98%
2005 24.484.000 33.44%
2006 18.755.000 -30.55%
2007 17.938.000 -4.55%
2008 23.030.000 22.11%
2009 27.000.000 14.7%
2010 29.386.000 8.12%
2011 34.317.000 14.37%
2012 35.788.000 4.11%
2013 40.555.000 11.75%
2014 53.867.000 24.71%
2015 71.257.000 24.4%
2016 63.795.000 -11.7%
2017 75.700.000 15.73%
2018 99.742.000 24.1%
2019 105.051.000 5.05%
2020 104.663.000 -0.37%
2021 105.467.000 0.76%
2022 106.805.000 1.25%
2023 82.520.000 -29.43%
2023 106.776.000 22.72%
2024 107.304.000 0.49%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

BioGaia AB (publ) General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 10.925.000
2003 8.584.000 -27.27%
2004 7.948.000 -8%
2005 7.726.000 -2.87%
2006 6.847.000 -12.84%
2007 7.487.000 8.55%
2008 8.193.000 8.62%
2009 8.996.000 8.93%
2010 9.849.000 8.66%
2011 13.014.000 24.32%
2012 13.423.000 3.05%
2013 14.356.000 6.5%
2014 17.666.000 18.74%
2015 18.475.000 4.38%
2016 20.893.000 11.57%
2017 22.063.000 5.3%
2018 27.653.000 20.21%
2019 24.609.000 -12.37%
2020 26.128.000 5.81%
2021 42.546.000 38.59%
2022 39.818.000 -6.85%
2023 31.736.000 -25.47%
2023 39.249.000 19.14%
2024 23.024.000 -70.47%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

BioGaia AB (publ) EBITDA
Year EBITDA Growth
2002 47.378.000
2003 19.609.000 -141.61%
2004 27.904.000 29.73%
2005 -15.384.000 281.38%
2006 7.278.000 311.38%
2007 14.743.000 50.63%
2008 34.656.000 57.46%
2009 57.320.000 39.54%
2010 72.623.000 21.07%
2011 108.280.000 32.93%
2012 435.046.000 75.11%
2013 85.398.000 -409.43%
2014 194.824.000 56.17%
2015 157.065.000 -24.04%
2016 202.085.000 22.28%
2017 245.043.000 17.53%
2018 285.546.000 14.18%
2019 258.520.000 -10.45%
2020 248.835.000 -3.89%
2021 281.085.000 11.47%
2022 393.312.000 28.53%
2023 542.084.000 27.44%
2023 466.190.000 -16.28%
2024 589.324.000 20.89%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

BioGaia AB (publ) Gross Profit
Year Gross Profit Growth
2002 14.458.000
2003 24.645.000 41.33%
2004 24.800.000 0.63%
2005 38.704.000 35.92%
2006 59.156.000 34.57%
2007 71.458.000 17.22%
2008 96.956.000 26.3%
2009 135.310.000 28.35%
2010 158.883.000 14.84%
2011 216.265.000 26.53%
2012 557.073.000 61.18%
2013 214.164.000 -160.12%
2014 350.464.000 38.89%
2015 336.584.000 -4.12%
2016 387.807.000 13.21%
2017 463.348.000 16.3%
2018 555.914.000 16.65%
2019 563.999.000 1.43%
2020 546.918.000 -3.12%
2021 582.950.000 6.18%
2022 801.930.000 27.31%
2023 943.388.000 14.99%
2023 950.190.000 0.72%
2024 1.136.164.000 16.37%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

BioGaia AB (publ) Net Profit
Year Net Profit Growth
2002 38.563.000
2003 13.055.000 -195.39%
2004 23.250.000 43.85%
2005 -19.825.000 217.28%
2006 2.720.000 828.86%
2007 19.659.000 86.16%
2008 36.121.000 45.57%
2009 36.045.000 -0.21%
2010 47.168.000 23.58%
2011 76.369.000 38.24%
2012 326.970.000 76.64%
2013 61.722.000 -429.75%
2014 147.406.000 58.13%
2015 121.408.000 -21.41%
2016 227.568.000 46.65%
2017 180.564.000 -26.03%
2018 214.890.000 15.97%
2019 187.347.000 -14.7%
2020 179.730.000 -4.24%
2021 196.273.000 8.43%
2022 373.773.000 47.49%
2023 406.004.000 7.94%
2023 365.352.000 -11.13%
2024 444.040.000 17.72%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

BioGaia AB (publ) Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 1 0%
2011 1 0%
2012 4 100%
2013 1 0%
2014 2 100%
2015 1 0%
2016 3 50%
2017 2 0%
2018 2 0%
2019 2 0%
2020 2 -100%
2021 2 0%
2022 4 66.67%
2023 4 25%
2023 4 -33.33%
2024 4 25%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

BioGaia AB (publ) Free Cashflow
Year Free Cashflow Growth
2002 11.819.000
2003 17.332.000 31.81%
2004 19.760.000 12.29%
2005 -11.695.000 268.96%
2006 -1.903.000 -514.56%
2007 3.083.000 161.73%
2008 16.831.000 81.68%
2009 50.395.000 66.6%
2010 68.325.000 26.24%
2011 56.613.000 -20.69%
2012 306.157.000 81.51%
2013 61.807.000 -395.34%
2014 99.902.000 38.13%
2015 89.571.000 -11.53%
2016 142.318.000 37.06%
2017 195.991.000 27.39%
2018 169.666.000 -15.52%
2019 108.831.000 -55.9%
2020 205.181.000 46.96%
2021 215.496.000 4.79%
2022 301.027.000 28.41%
2023 377.251.000 20.21%
2023 90.061.000 -318.88%
2024 116.884.000 22.95%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

BioGaia AB (publ) Operating Cashflow
Year Operating Cashflow Growth
2002 29.573.000
2003 22.588.000 -30.92%
2004 22.989.000 1.74%
2005 -9.969.000 330.6%
2006 -831.000 -1099.64%
2007 5.088.000 116.33%
2008 19.204.000 73.51%
2009 53.290.000 63.96%
2010 68.965.000 22.73%
2011 72.792.000 5.26%
2012 335.557.000 78.31%
2013 78.441.000 -327.78%
2014 124.383.000 36.94%
2015 117.501.000 -5.86%
2016 147.929.000 20.57%
2017 222.615.000 33.55%
2018 183.120.000 -21.57%
2019 147.855.000 -23.85%
2020 221.256.000 33.17%
2021 221.875.000 0.28%
2022 318.943.000 30.43%
2023 425.965.000 25.12%
2023 98.978.000 -330.36%
2024 119.125.000 16.91%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

BioGaia AB (publ) Capital Expenditure
Year Capital Expenditure Growth
2002 17.754.000
2003 5.256.000 -237.79%
2004 3.229.000 -62.77%
2005 1.726.000 -87.08%
2006 1.072.000 -61.01%
2007 2.005.000 46.53%
2008 2.373.000 15.51%
2009 2.895.000 18.03%
2010 640.000 -352.34%
2011 16.179.000 96.04%
2012 29.400.000 44.97%
2013 16.634.000 -76.75%
2014 24.481.000 32.05%
2015 27.930.000 12.35%
2016 5.611.000 -397.77%
2017 26.624.000 78.93%
2018 13.454.000 -97.89%
2019 39.024.000 65.52%
2020 16.075.000 -142.76%
2021 6.379.000 -152%
2022 17.916.000 64.39%
2023 48.714.000 63.22%
2023 8.917.000 -446.3%
2024 2.241.000 -297.9%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

BioGaia AB (publ) Equity
Year Equity Growth
2002 127.994.000
2003 114.848.000 -11.45%
2004 91.502.000 -25.51%
2005 71.779.000 -27.48%
2006 74.530.000 3.69%
2007 94.910.000 21.47%
2008 132.420.000 28.33%
2009 161.118.000 17.81%
2010 187.323.000 13.99%
2011 230.355.000 18.68%
2012 456.794.000 49.57%
2013 316.857.000 -44.16%
2014 344.591.000 8.05%
2015 395.833.000 12.95%
2016 415.180.000 4.66%
2017 463.888.000 10.5%
2018 508.121.000 8.71%
2019 507.874.000 -0.05%
2020 1.746.245.000 70.92%
2021 1.877.367.000 6.98%
2022 1.972.418.000 4.82%
2023 1.985.273.000 0.65%
2023 2.030.344.000 2.22%
2024 1.575.312.000 -28.89%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

BioGaia AB (publ) Assets
Year Assets Growth
2002 161.633.000
2003 135.902.000 -18.93%
2004 108.508.000 -25.25%
2005 87.153.000 -24.5%
2006 90.763.000 3.98%
2007 110.773.000 18.06%
2008 154.306.000 28.21%
2009 179.814.000 14.19%
2010 227.822.000 21.07%
2011 279.832.000 18.59%
2012 517.022.000 45.88%
2013 383.419.000 -34.85%
2014 415.608.000 7.75%
2015 473.178.000 12.17%
2016 488.978.000 3.23%
2017 576.112.000 15.12%
2018 659.973.000 12.71%
2019 665.900.000 0.89%
2020 1.913.282.000 65.2%
2021 2.128.054.000 10.09%
2022 2.213.966.000 3.88%
2023 2.304.253.000 3.92%
2023 2.333.189.000 1.24%
2024 1.900.708.000 -22.75%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

BioGaia AB (publ) Liabilities
Year Liabilities Growth
2002 33.639.000
2003 21.054.000 -59.77%
2004 17.006.000 -23.8%
2005 15.374.000 -10.62%
2006 16.233.000 5.29%
2007 15.863.000 -2.33%
2008 21.886.000 27.52%
2009 18.696.000 -17.06%
2010 40.499.000 53.84%
2011 49.477.000 18.15%
2012 60.228.000 17.85%
2013 66.562.000 9.52%
2014 71.017.000 6.27%
2015 77.345.000 8.18%
2016 73.798.000 -4.81%
2017 112.224.000 34.24%
2018 151.852.000 26.1%
2019 158.026.000 3.91%
2020 167.037.000 5.39%
2021 250.687.000 33.37%
2022 241.548.000 -3.78%
2023 318.980.000 24.27%
2023 302.845.000 -5.33%
2024 325.396.000 6.93%

BioGaia AB (publ) Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
13.56
Net Income per Share
3.98
Price to Earning Ratio
27.25x
Price To Sales Ratio
7.71x
POCF Ratio
27.94
PFCF Ratio
29.51
Price to Book Ratio
6.95
EV to Sales
6.98
EV Over EBITDA
17.7
EV to Operating CashFlow
24.39
EV to FreeCashFlow
26.7
Earnings Yield
0.04
FreeCashFlow Yield
0.03
Market Cap
10,56 Bil.
Enterprise Value
9,56 Bil.
Graham Number
37.37
Graham NetNet
6.76

Income Statement Metrics

Net Income per Share
3.98
Income Quality
0.86
ROE
0.21
Return On Assets
0.21
Return On Capital Employed
0.28
Net Income per EBT
0.78
EBT Per Ebit
1.08
Ebit per Revenue
0.35
Effective Tax Rate
0.22

Margins

Sales, General, & Administrative to Revenue
0.03
Research & Developement to Revenue
0.07
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.74
Operating Profit Margin
0.35
Pretax Profit Margin
0.37
Net Profit Margin
0.29

Dividends

Dividend Yield
0.06
Dividend Yield %
6.37
Payout Ratio
1.73
Dividend Per Share
6.9

Operating Metrics

Operating Cashflow per Share
3.88
Free CashFlow per Share
3.54
Capex to Operating CashFlow
0.09
Capex to Revenue
0.02
Capex to Depreciation
1.4
Return on Invested Capital
0.24
Return on Tangible Assets
0.24
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0.34

Balance Sheet

Cash per Share
9,98
Book Value per Share
15,60
Tangible Book Value per Share
13.42
Shareholders Equity per Share
15.6
Interest Debt per Share
0.03
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-1.87
Current Ratio
6.49
Tangible Asset Value
1,35 Bil.
Net Current Asset Value
1,10 Bil.
Invested Capital
1642156000
Working Capital
1,21 Bil.
Intangibles to Total Assets
0.12
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

BioGaia AB (publ) Dividends
Year Dividends Growth
2009 0
2010 1 0%
2011 1 100%
2012 5 75%
2013 6 20%
2014 4 -66.67%
2015 2 -200%
2016 2 0%
2017 4 75%
2018 9 55.56%
2019 6 -80%
2020 4 -66.67%
2021 3 0%
2022 11 72.73%
2023 1 -1000%
2024 7 83.33%

BioGaia AB (publ) Profile

About BioGaia AB (publ)

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pylori–the gastric ulcer bacterium; and low bone density. It offers its products under the BioGaia brand name. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.

CEO
Ms. Theresa P. Agnew
Employee
220
Address
Kungsbroplan 3
Stockholm, 112 27

BioGaia AB (publ) Executives & BODs

BioGaia AB (publ) Executives & BODs
# Name Age
1 Mr. Gianfranco Grompone
Chief Scientific Officer and Vice President of Research & Development
70
2 Ludvig Milesson
Chief Operating Officer
70
3 Ms. Caroline Mofors
Chief Legal Officer
70
4 Ms. Linda Hagglund
Vice President of Marketing
70
5 Ms. Angelika Kjelldorff
Chief HR Officer
70
6 Sebastian Heimfors
Vice President & Chief Commercial Officer
70
7 Jonathan Gromark
Sustainability Manager
70
8 Ms. Theresa P. Agnew
Chief Executive Officer & President
70
9 Mr. Peter Rothschild M.Sc. Econ., MBA
Founder & Chairman
70
10 Mr. Alexander Kotsinas M.Sc. (Eng.).
Executive Vice President & Chief Financial Officer
70

BioGaia AB (publ) Competitors

Biotage AB (publ) Logo
Biotage AB (publ)

BIOT.ST

(2.8)
CellaVision AB (publ) Logo
CellaVision AB (publ)

CEVI.ST

(3.5)
Sectra AB (publ) Logo
Sectra AB (publ)

SECT-B.ST

(3.0)
Elekta AB (publ) Logo
Elekta AB (publ)

EKTA-B.ST

(2.0)
Probi AB (publ) Logo
Probi AB (publ)

PROB.ST

(2.0)